SOT 2016 – Ocular Gene and Cell Therapy Safety Studies: Critical Ophthalmology Endpoints to Consider

//SOT 2016 – Ocular Gene and Cell Therapy Safety Studies: Critical Ophthalmology Endpoints to Consider

SOT 2016 – Ocular Gene and Cell Therapy Safety Studies: Critical Ophthalmology Endpoints to Consider

By | 2016-04-15T12:23:32+00:00 March 31st, 2016|Video|Comments Off on SOT 2016 – Ocular Gene and Cell Therapy Safety Studies: Critical Ophthalmology Endpoints to Consider

About the Author:

MPI Research, with global headquarters in Mattawan, Mich., provides safety evaluation, discovery, bioanalytical and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries. The company offers comprehensive imaging solutions including preclinical imaging, radiochemistry, and data analysis. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world.